History
UCB was founded on 18 January 1928 by Emmanuel Janssen, a Belgian businessman. Initially focused on industrial chemicals ( it was one of the first companies to distill amonia from coal ), the company also included a small pharmaceutical division based around Meurice Laboratories.
In the early 1950s, UCB set up a research centre where new medicines such as Atarax (hydroxyzine) were developed. Successful sales enabled the pharmaceutical division to expand, and led to the discovery of another important compound, called piracetam. This was marketed in the 1970s as Nootropil and used to treat memory and balance problems. It remains one of UCB's key products. At this time, UCB was a company focusing on three core areas: pharmaceuticals, chemicals and films.
The success of Nootropil made it possible for UCB to build a modern pharmaceutical site in Braine-l'Alleud, south of Brussels. There, UCB developed Zyrtec (cetirizine), a blockbuster antihistamine. Other important products have followed including Keppra (levetiracetam), Xyzal (levocetirizine), and Cimzia (certolizumab pegol), which was acquired through the acquisition of Celltech.
At the end of 2002, the chemicals and films divisions were merged and UCB added the resins, additives and adhesives activities of Solutia, to form the surface specialties division. The films part has since been sold to Innovia Films in September 2004. The chemicals division, Methylamines and Derivatives was spun off and later sold to form the company Taminco.
In May 2004, UCB acquired the British biotechnology company Celltech, followed in March 2005 by the sale of the surface specialties business to Cytec Industries. By divesting all of its non-pharmaceutical activities, and acquiring Celltech, UCB transformed itself into a global biopharmaceutical company.
In 2006, UCB started the purchase of the German pharmaceutical company Schwarz for €4.4 billion. As of July 2007, UCB holds approximately 87% of Schwarz's outstanding shares. The purchase of Schwarz enabled UCB to introduce two new drugs against CNS disorders: Neupro (rotigotine), a transdermal patch for treatment of Parkinson's disease and Vimpat (lacosamide), a new anticonvulsant. Another new drug of the Schwarz portfolio, Toviaz (fesoterodine), a compound to treat overactive bladder, was licensed to Pfizer in 2006.
Read more about this topic: UCB (company)
Famous quotes containing the word history:
“When the coherence of the parts of a stone, or even that composition of parts which renders it extended; when these familiar objects, I say, are so inexplicable, and contain circumstances so repugnant and contradictory; with what assurance can we decide concerning the origin of worlds, or trace their history from eternity to eternity?”
—David Hume (1711–1776)
“The history of progress is written in the blood of men and women who have dared to espouse an unpopular cause, as, for instance, the black man’s right to his body, or woman’s right to her soul.”
—Emma Goldman (1869–1940)
“My good friends, this is the second time in our history that there has come back from Germany to Downing Street peace with honour. I believe it is peace for our time. We thank you from the bottom of our hearts. And now I recommend you to go home and sleep quietly in your beds.”
—Neville Chamberlain (1869–1940)